Oculis Holding AG Ordinary shares

Oculis Holding AG has signed an asset purchase agreement to acquire all worldwide development and commercial rights to its lead neuro-ophthalmology candidate Privosegtor from Accure Therapeutics. The deal terminates Oculis’ existing license agreement with Accure, eliminating associated milestone payments and royalties while securing greater economic upside. Total consideration includes a $3.8 million upfront cash payment and up to 2,050,000 Oculis ordinary shares, consisting of upfront shares subject to a two-year lockup and earnout shares tied to development and regulatory milestones. The transaction also covers an early-stage preclinical neurology candidate, ACT-02, in a separate closing. The Privosegtor closing is expected by February 28, 2027, and the ACT-02 closing by March 31, 2027.

Oculis Holding AG reported cash, cash equivalents, and short-term investments of $282.3 million as of June 30, 2026, providing a cash runway into the second half of 2029. The company is advancing its pivot to neuro-ophthalmology with Privosegtor as the lead late-stage asset, progressing site activations in the PIONEER-1 registrational trial for optic neuritis and receiving positive FDA pre-IND feedback to expand into acute multiple sclerosis relapses, with an IND submission planned for the fourth quarter of 2026. Enrollment in the PREDICT-1 genotype-based registrational trial of Licaminlimab in dry eye disease is proceeding as planned, with all sites activated and over 45% of patients randomized, and topline results are expected around year-end. Following the DIAMOND topline results in May, Oculis does not plan to pursue an FDA regulatory filing for OCS-01 in diabetic macular edema. The company will host an R&D Day in the fourth quarter to share updates on Privosegtor's clinical development.

Oculis Holding AG announced positive FDA pre-IND feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis relapses. The FDA Division of Neurology confirmed that existing Privosegtor data can be cross-referenced for a new Investigational New Drug application, which Oculis plans to submit in the fourth quarter of 2026. The company also intends to host an R&D Day in the fourth quarter of 2026 to detail the pivotal development program for Privosegtor in acute MS relapses and provide an update on the PIONEER program in optic neuropathies. In pre-market trading on NasdaqGM, Oculis shares rose 4.97 percent to $11.87.